Effects of IVB on the area of capillary nonperfusion in BRVO eyes

Article

Occurrence of, a significantly increased area of capillary nonperfusion is significantly low in eyes with branch retinal vein occlusion (BRVO) after administration of intravitreal bevacizumab (IVB),

Occurrence of, a significantly increased area of capillary nonperfusion is significantly low in eyes with branch retinal vein occlusion (BRVO) after administration of intravitreal bevacizumab (IVB), according to a study published in Retina.

Dr Terui Takayuki et al., Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan, studied 58 eyes of 58 patients with macular oedema secondary to BRVO. One month before and one month after IVB, fluorescein angiography was performed on all patients. Early-phase fluorescein angiography imaging was used to measure the area of capillary nonperfusion and blockages of the fluorescence by the retinal haemorrhage were determined with retinal photographs.

Before IVB 37 of the 58 eyes did not show any signs of capillary nonperfusion and after one month of IVB 3 of the 37 eyes developed capillary nonperfusion. The area of nonperfusion in these 3 eyes was 0.13, 0.47 and 0.60 optic disc area (DA).

Before IVB 21 of the 58 eyes had capillary nonperfusion and the mean area was 3.45 ± 4.66 DA before the IVB and 3.45 ± 5.19 DA 1 month after the IVB.

Only one eye of the 58 studied presented with an increase in the area of capillary nonperfusion after IVB. The incidence of an increase in capillary nonperfusion area post IVB treatment is significantly low in eyes with BRVO.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.